- The FDA approves the use of Janssen Pharmaceuticals' (NYSE:JNJ) INVOKAMET, a fixed-dose combination of INVOKANA (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes (T2D).
- INVOKAMET was first approved in the U.S. in August 2014 as an adjunct to diet and exercise to improve blood glucose control in adults with T2D not adequately controlled by either canagliflozin or metformin or who are already being treated with both medications separately.
FDA approves expanded label for Janssen Pharma's T2D med Invokamet
Recommended For You
More Trending News
About JNJ Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| JNJ | - | - |
| Johnson & Johnson | ||